Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hatchtech Pty Ltd is an innovative biotechnology company developing novel solutions for everyday health problems based in Melbourne, Australia. Its lead development product, Xeglyze™, is a single dose, single treatment, topical prescription product for the control of head lice. Xeglyze was approved by the FDA in July 2020 and is currently available for partnering.

List your booth number for exhibitions, ask us